Low serum adiponectin predicts 10-year risk of type 2 diabetes and hba1c independently of obesity, lipids, and inflammation: Whitehall II study

A. G. Tabák, E. J. Brunner, M. A. Miller, S. Karanam, P. G. McTernan, F. P. Cappuccio, D. R. Witte

Research output: Contribution to journalArticle

30 Citations (Scopus)


Our aim of the present work was to study the effect of serum adiponectin on incident diabetes and HbA1c values. We measured baseline serum adiponectin levels in a nested case-control selection (n=140) of the Whitehall II Cohort. Participants (mean [SD] age 50.9 [6.3] years) had no prevalent diabetes or CHD at baseline. Cases (n=55) had incident diabetes according to an oral glucose tolerance test during follow-up (mean: 11.5±3.0 years). Adiponectin levels were lower among cases (9.3g/ml, 3.2 [median; IQR] vs. 10.5; 3.6, p=0.01). The risk of incident diabetes decreased by 11% (p=0.03) for 1g/ml higher adiponectin levels. Higher adiponectin levels were associated with lower HbA1c at follow-up (p<0.05). Both associations were stable to adjustment for age, sex, body mass index, systolic blood pressure, and serum lipids, and for the case of HbA1c, also for C-reactive protein (all p<0.05). The observed robust, prospective associations support that adiponectin is an independent predictor of diabetes and the degree of glycaemic impairment.

Original languageEnglish
Pages (from-to)626-629
Number of pages4
JournalHormone and Metabolic Research
Issue number8
Publication statusPublished - Nov 2 2009



  • Adipokines
  • C-reactive protein
  • Follow-up studies
  • Glycosylated
  • Haemoglobin A

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this